PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 23322784-5 2013 bNOS also promoted resistance to the pharmaceutical antibiotics that act on the cell envelope such as vancomycin and daptomycin. Daptomycin 117-127 nitric oxide synthase 1 Homo sapiens 0-4 25060342-4 2013 RESULTS: Total health-care costs per patient were GBP 6,214 and GBP 6,491 for daptomycin and vancomycin, respectively. Daptomycin 78-88 guanylate binding protein family member 6 Homo sapiens 64-69 24738238-0 2013 [Estimation of MRSA susceptibility to oxacillin, cefoxitine, vancomycin and daptomycin]. Daptomycin 76-86 solute carrier family 9 member A6 Homo sapiens 15-19 24738238-3 2013 There is lately being observed a tendency towards emergence of strains with lower susceptibility to the last reserve drugs protecting from MRSA, i. e. vancomycin and daptomycin. Daptomycin 166-176 solute carrier family 9 member A6 Homo sapiens 139-143 24738238-5 2013 The results of our study on estimation of susceptibility of 316 MRSA isolates from several regions of Russia to oxacillin, cefoxitine, vancomycin and daptomycin are presented herein. Daptomycin 150-160 solute carrier family 9 member A6 Homo sapiens 64-68 24738238-10 2013 The MRSA isolates were highly susceptible to daptomycin, while high levels of the MIC (2 mcg/ml) were characteristic of 2.8 +/- 1% of the isolates. Daptomycin 45-55 solute carrier family 9 member A6 Homo sapiens 4-8 22985884-2 2012 Daptomycin (DAP) is a cyclic anionic lipopeptide recommended for treatment of skin infections, bacteremia, and right-sided endocarditis caused by MRSA. Daptomycin 0-10 death associated protein Homo sapiens 12-15 22253738-0 2012 Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains. Daptomycin 38-48 mitochondrial antiviral signaling protein Homo sapiens 128-133 22644021-10 2012 Daptomycin plus ceftriaxone versus ceftriaxone significantly (P < 0.04) lowered CSF concentrations of monocyte chemoattractant protein 1 (MCP-1), MIP-1alpha, and interleukin 6 (IL-6) at 6 h and MIP-1alpha, IL-6, and IL-10 at 22 h after initiation of therapy, led to significantly (P < 0.01) less apoptosis, and significantly (P < 0.01) improved hearing capacity. Daptomycin 0-10 C-C motif chemokine ligand 2 Rattus norvegicus 105-139 22644021-10 2012 Daptomycin plus ceftriaxone versus ceftriaxone significantly (P < 0.04) lowered CSF concentrations of monocyte chemoattractant protein 1 (MCP-1), MIP-1alpha, and interleukin 6 (IL-6) at 6 h and MIP-1alpha, IL-6, and IL-10 at 22 h after initiation of therapy, led to significantly (P < 0.01) less apoptosis, and significantly (P < 0.01) improved hearing capacity. Daptomycin 0-10 C-C motif chemokine ligand 2 Rattus norvegicus 141-146 22644021-10 2012 Daptomycin plus ceftriaxone versus ceftriaxone significantly (P < 0.04) lowered CSF concentrations of monocyte chemoattractant protein 1 (MCP-1), MIP-1alpha, and interleukin 6 (IL-6) at 6 h and MIP-1alpha, IL-6, and IL-10 at 22 h after initiation of therapy, led to significantly (P < 0.01) less apoptosis, and significantly (P < 0.01) improved hearing capacity. Daptomycin 0-10 C-C motif chemokine ligand 3 Rattus norvegicus 149-159 22644021-10 2012 Daptomycin plus ceftriaxone versus ceftriaxone significantly (P < 0.04) lowered CSF concentrations of monocyte chemoattractant protein 1 (MCP-1), MIP-1alpha, and interleukin 6 (IL-6) at 6 h and MIP-1alpha, IL-6, and IL-10 at 22 h after initiation of therapy, led to significantly (P < 0.01) less apoptosis, and significantly (P < 0.01) improved hearing capacity. Daptomycin 0-10 interleukin 6 Rattus norvegicus 165-178 22644021-10 2012 Daptomycin plus ceftriaxone versus ceftriaxone significantly (P < 0.04) lowered CSF concentrations of monocyte chemoattractant protein 1 (MCP-1), MIP-1alpha, and interleukin 6 (IL-6) at 6 h and MIP-1alpha, IL-6, and IL-10 at 22 h after initiation of therapy, led to significantly (P < 0.01) less apoptosis, and significantly (P < 0.01) improved hearing capacity. Daptomycin 0-10 interleukin 6 Rattus norvegicus 180-184 22644021-10 2012 Daptomycin plus ceftriaxone versus ceftriaxone significantly (P < 0.04) lowered CSF concentrations of monocyte chemoattractant protein 1 (MCP-1), MIP-1alpha, and interleukin 6 (IL-6) at 6 h and MIP-1alpha, IL-6, and IL-10 at 22 h after initiation of therapy, led to significantly (P < 0.01) less apoptosis, and significantly (P < 0.01) improved hearing capacity. Daptomycin 0-10 C-C motif chemokine ligand 3 Rattus norvegicus 197-207 22644021-10 2012 Daptomycin plus ceftriaxone versus ceftriaxone significantly (P < 0.04) lowered CSF concentrations of monocyte chemoattractant protein 1 (MCP-1), MIP-1alpha, and interleukin 6 (IL-6) at 6 h and MIP-1alpha, IL-6, and IL-10 at 22 h after initiation of therapy, led to significantly (P < 0.01) less apoptosis, and significantly (P < 0.01) improved hearing capacity. Daptomycin 0-10 interleukin 6 Rattus norvegicus 209-213 22644021-10 2012 Daptomycin plus ceftriaxone versus ceftriaxone significantly (P < 0.04) lowered CSF concentrations of monocyte chemoattractant protein 1 (MCP-1), MIP-1alpha, and interleukin 6 (IL-6) at 6 h and MIP-1alpha, IL-6, and IL-10 at 22 h after initiation of therapy, led to significantly (P < 0.01) less apoptosis, and significantly (P < 0.01) improved hearing capacity. Daptomycin 0-10 interleukin 10 Rattus norvegicus 219-224 22495870-5 2012 To our knowledge, this article describes the first case of daptomycin-resistant heterogenous vancomycin intermediate-resistant Staphylococcus aureus (hVISA) in an 82-year-old man undergoing elective total knee arthroplasty in Queensland, Australia, with a subsequent deep prosthetic joint infection.A literature review is presented, and the increasing number of multi-resistant organisms and their implications for orthopedics are discussed. Daptomycin 59-69 mitochondrial antiviral signaling protein Homo sapiens 150-155 22958379-13 2012 PFGE revealed a diverse population of DNSE, which along with both increasing numbers of DNSE detected yearly and increasing annual rates of daptomycin usage, suggests the emergence of DNSE under antimicrobial pressure. Daptomycin 140-150 sulfatase modifying factor 2 Homo sapiens 0-4 22253738-0 2012 Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains. Daptomycin 38-48 mitochondrial antiviral signaling protein Homo sapiens 129-133 22253738-5 2012 Our results show that hVISA and VISA present common features that distinguish them from Vancomycin-Susceptible Staphylococcus aureus (VSSA), responsible for the intermediate glycopeptide resistance i.e. an increased cell-wall turnover, an increased positive cell-wall charge responsible for a repulsion mechanism towards vancomycin and daptomycin, and reduced agr-functionality. Daptomycin 336-346 mitochondrial antiviral signaling protein Homo sapiens 22-27 22253738-5 2012 Our results show that hVISA and VISA present common features that distinguish them from Vancomycin-Susceptible Staphylococcus aureus (VSSA), responsible for the intermediate glycopeptide resistance i.e. an increased cell-wall turnover, an increased positive cell-wall charge responsible for a repulsion mechanism towards vancomycin and daptomycin, and reduced agr-functionality. Daptomycin 336-346 mitochondrial antiviral signaling protein Homo sapiens 23-27 22253738-7 2012 Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways responsible for the intermediate vancomycin resistance in VISA. Daptomycin 15-25 mitochondrial antiviral signaling protein Homo sapiens 57-62 22253738-7 2012 Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways responsible for the intermediate vancomycin resistance in VISA. Daptomycin 15-25 mitochondrial antiviral signaling protein Homo sapiens 58-62 22253738-7 2012 Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways responsible for the intermediate vancomycin resistance in VISA. Daptomycin 15-25 mitochondrial antiviral signaling protein Homo sapiens 67-71 22253738-7 2012 Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways responsible for the intermediate vancomycin resistance in VISA. Daptomycin 15-25 mitochondrial antiviral signaling protein Homo sapiens 148-153 22253738-7 2012 Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways responsible for the intermediate vancomycin resistance in VISA. Daptomycin 15-25 mitochondrial antiviral signaling protein Homo sapiens 67-71 21502617-8 2011 Mutations in one of the seven candidate genes (EF0631), encoding a putative cardiolipin synthase, were found in each of the adapted E. faecalis V583 strains as well as in daptomycin-resistant E. faecalis and E. faecium clinical isolates. Daptomycin 171-181 cardiolipin synthase Enterococcus faecalis V583 47-53 22253738-8 2012 Daptomycin can also induce a charge repulsion mechanism both in hVISA and VISA increasing the activity of the mprF. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 64-69 22253738-8 2012 Daptomycin can also induce a charge repulsion mechanism both in hVISA and VISA increasing the activity of the mprF. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 65-69 21929771-11 2011 The parameters of infection including, fibrinogen (p = 0.03), white blood cell count (p = 0.001) and C-reactive protein (p = 0.0001) were significantly reduced after daptomycin application. Daptomycin 166-176 fibrinogen beta chain Homo sapiens 39-49 21929771-11 2011 The parameters of infection including, fibrinogen (p = 0.03), white blood cell count (p = 0.001) and C-reactive protein (p = 0.0001) were significantly reduced after daptomycin application. Daptomycin 166-176 C-reactive protein Homo sapiens 101-119 21596511-3 2011 The method presented good fit (r>0.999) over the quantification range of 0.01-10 mug mL-1 with the lower limit of quantitation (LLOQ) being 0.01 mug mL-1 of human plasma for DPT. Daptomycin 177-180 L1 cell adhesion molecule Mus musculus 88-92 21596511-3 2011 The method presented good fit (r>0.999) over the quantification range of 0.01-10 mug mL-1 with the lower limit of quantitation (LLOQ) being 0.01 mug mL-1 of human plasma for DPT. Daptomycin 177-180 L1 cell adhesion molecule Mus musculus 152-156 21502617-9 2011 Alleles of EF0631 from daptomycin-resistant strains are dominant in trans and confer daptomycin resistance upon a susceptible host. Daptomycin 23-33 cardiolipin synthase Enterococcus faecalis V583 11-17 21502617-9 2011 Alleles of EF0631 from daptomycin-resistant strains are dominant in trans and confer daptomycin resistance upon a susceptible host. Daptomycin 85-95 cardiolipin synthase Enterococcus faecalis V583 11-17 21502617-10 2011 These results demonstrate a mechanism of enterococcal daptomycin resistance that is genetically distinct from that occurring in staphylococci and indicate that enterococci possessing alternate EF0631 alleles are selected for during daptomycin therapy. Daptomycin 54-64 cardiolipin synthase Enterococcus faecalis V583 193-199 21502617-10 2011 These results demonstrate a mechanism of enterococcal daptomycin resistance that is genetically distinct from that occurring in staphylococci and indicate that enterococci possessing alternate EF0631 alleles are selected for during daptomycin therapy. Daptomycin 232-242 cardiolipin synthase Enterococcus faecalis V583 193-199 21502620-1 2011 There are currently few or no published data on the amount of cerebrospinal fluid (CSF) penetration of daptomycin in patients with suspected or documented neurosurgical infections. Daptomycin 103-113 colony stimulating factor 2 Homo sapiens 83-86 21502620-2 2011 We conducted a prospective study, assessing the pharmacokinetics and CSF penetration of a single intravenous daptomycin dose administered at 10 mg/kg, based on total body weight (TBW), in six neurosurgical patients with indwelling external CSF shunts with suspected or documented meningitis or ventriculitis. Daptomycin 109-119 colony stimulating factor 2 Homo sapiens 69-72 21502620-2 2011 We conducted a prospective study, assessing the pharmacokinetics and CSF penetration of a single intravenous daptomycin dose administered at 10 mg/kg, based on total body weight (TBW), in six neurosurgical patients with indwelling external CSF shunts with suspected or documented meningitis or ventriculitis. Daptomycin 109-119 colony stimulating factor 2 Homo sapiens 240-243 21502620-6 2011 The mean daptomycin penetration, determined by the area under the concentration-time curve in CSF (AUC(CSF))/(AUC(serum) ratio), was 0.8%. Daptomycin 9-19 colony stimulating factor 2 Homo sapiens 94-97 21502620-6 2011 The mean daptomycin penetration, determined by the area under the concentration-time curve in CSF (AUC(CSF))/(AUC(serum) ratio), was 0.8%. Daptomycin 9-19 colony stimulating factor 2 Homo sapiens 99-107 21502620-8 2011 Additional pharmacokinetic studies evaluating multiple and/or higher dosages of daptomycin are necessary in human subjects to better characterize the CSF penetration of daptomycin in neurosurgical patients. Daptomycin 169-179 colony stimulating factor 2 Homo sapiens 150-153 21839399-6 2011 Primary outcome was the incremental cost-effectiveness ratio between linezolid and vancomycin, daptomycin and vancomycin, and linezolid and daptomycin in MRSA cSSSI. Daptomycin 140-150 solute carrier family 9 member A6 Homo sapiens 154-164 21321148-3 2011 Three clinical MRSA isolates, including one heterogeneous vancomycin-intermediate S. aureus (hVISA) isolate and one vancomycin-intermediate S. aureus (VISA) isolate, were exposed to daptomycin at 10 or 6 mg/kg of body weight/day for 8 days using a starting inoculum of ~10(9) CFU/g of vegetations, with dose escalation and de-escalation initiated on the fourth day. Daptomycin 182-192 mitochondrial antiviral signaling protein Homo sapiens 93-98 21455712-0 2011 Glycopeptide and daptomycin resistance in community-associated MRSA in the UK. Daptomycin 17-27 solute carrier family 9 member A6 Homo sapiens 63-67 21321148-3 2011 Three clinical MRSA isolates, including one heterogeneous vancomycin-intermediate S. aureus (hVISA) isolate and one vancomycin-intermediate S. aureus (VISA) isolate, were exposed to daptomycin at 10 or 6 mg/kg of body weight/day for 8 days using a starting inoculum of ~10(9) CFU/g of vegetations, with dose escalation and de-escalation initiated on the fourth day. Daptomycin 182-192 mitochondrial antiviral signaling protein Homo sapiens 94-98 20345716-0 2010 Phosphatidylglycerol and daptomycin synergistically inhibit tissue factor-induced coagulation in the prothrombin time test. Daptomycin 25-35 coagulation factor III, tissue factor Homo sapiens 60-73 21393156-0 2011 Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 80-84 21393156-0 2011 Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 104-108 21393156-0 2011 Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 110-115 21393156-5 2011 RESULTS: The percentage of daptomycin non-susceptible isolates was 0% for vancomycin-susceptible S. aureus (VSSA) (Etest and BMD), for hVISA it was 26% by Etest and 15% by BMD, and for VISA 62% by Etest and 38% by BMD. Daptomycin 27-37 mitochondrial antiviral signaling protein Homo sapiens 136-140 21393156-6 2011 Population analysis profile testing demonstrated daptomycin heteroresistance among the hVISA and VISA strains tested. Daptomycin 49-59 mitochondrial antiviral signaling protein Homo sapiens 87-92 21393156-6 2011 Population analysis profile testing demonstrated daptomycin heteroresistance among the hVISA and VISA strains tested. Daptomycin 49-59 mitochondrial antiviral signaling protein Homo sapiens 88-92 21393156-7 2011 CONCLUSIONS: This is the highest rate of daptomycin non-susceptibility reported among hVISA isolates to date. Daptomycin 41-51 mitochondrial antiviral signaling protein Homo sapiens 86-91 21393156-8 2011 Clinicians should exhibit caution when using daptomycin in situations where serious hVISA or VISA infection is a possibility. Daptomycin 45-55 mitochondrial antiviral signaling protein Homo sapiens 84-89 21393156-8 2011 Clinicians should exhibit caution when using daptomycin in situations where serious hVISA or VISA infection is a possibility. Daptomycin 45-55 mitochondrial antiviral signaling protein Homo sapiens 85-89 21266054-6 2011 RESULTS: RAW264.7 cells exposed to either LAC or MW2 in the presence of daptomycin secreted less TNF than in the presence of vancomycin. Daptomycin 72-82 tumor necrosis factor Mus musculus 97-100 21306448-7 2011 Intriguingly, specific point mutations in mprF cause resistance to the CAMP-like antibiotic daptomycin in a yet unclear way that may involve altered Lys-PG synthesis and/or Lys-PG flipping capacities. Daptomycin 92-102 cathelicidin antimicrobial peptide Homo sapiens 71-75 20580568-0 2010 IFN-gamma enhances killing of methicillin-resistant Staphylococcus aureus by human monocytes more effectively than GM-CSF in the presence of daptomycin and other antibiotics. Daptomycin 141-151 interferon gamma Homo sapiens 0-9 20580568-8 2010 IFN-gamma enhanced rapid intracellular killing of MRSA in the presence of triple-drug treatment or Dap alone. Daptomycin 99-102 interferon gamma Homo sapiens 0-9 19887592-5 2009 A variety of antibiotics were used in combination with daptomycin, but the patient remained febrile, with positive blood cultures revealing vancomycin minimum inhibitory concentration (MIC) greater than 256 microg/mL and daptomycin MIC 3 microg/mL (and later, 4 microg/mL). Daptomycin 221-231 CD9 molecule Homo sapiens 232-237 20065062-3 2010 Daptomycin led to lower CSF concentrations of interleukin 1beta (IL-1beta), IL-10, IL-18, monocyte chemoattractant protein 1 (MCP-1), and macrophage inflammatory protein 1 alpha (MIP-1alpha) (P < 0.05). Daptomycin 0-10 interleukin 1 beta Homo sapiens 46-63 20065062-3 2010 Daptomycin led to lower CSF concentrations of interleukin 1beta (IL-1beta), IL-10, IL-18, monocyte chemoattractant protein 1 (MCP-1), and macrophage inflammatory protein 1 alpha (MIP-1alpha) (P < 0.05). Daptomycin 0-10 interleukin 1 beta Homo sapiens 65-73 20065062-3 2010 Daptomycin led to lower CSF concentrations of interleukin 1beta (IL-1beta), IL-10, IL-18, monocyte chemoattractant protein 1 (MCP-1), and macrophage inflammatory protein 1 alpha (MIP-1alpha) (P < 0.05). Daptomycin 0-10 interleukin 10 Homo sapiens 76-81 20065062-3 2010 Daptomycin led to lower CSF concentrations of interleukin 1beta (IL-1beta), IL-10, IL-18, monocyte chemoattractant protein 1 (MCP-1), and macrophage inflammatory protein 1 alpha (MIP-1alpha) (P < 0.05). Daptomycin 0-10 interleukin 18 Homo sapiens 83-88 20065062-3 2010 Daptomycin led to lower CSF concentrations of interleukin 1beta (IL-1beta), IL-10, IL-18, monocyte chemoattractant protein 1 (MCP-1), and macrophage inflammatory protein 1 alpha (MIP-1alpha) (P < 0.05). Daptomycin 0-10 C-C motif chemokine ligand 2 Homo sapiens 90-124 20065062-3 2010 Daptomycin led to lower CSF concentrations of interleukin 1beta (IL-1beta), IL-10, IL-18, monocyte chemoattractant protein 1 (MCP-1), and macrophage inflammatory protein 1 alpha (MIP-1alpha) (P < 0.05). Daptomycin 0-10 C-C motif chemokine ligand 2 Homo sapiens 126-131 20065062-3 2010 Daptomycin led to lower CSF concentrations of interleukin 1beta (IL-1beta), IL-10, IL-18, monocyte chemoattractant protein 1 (MCP-1), and macrophage inflammatory protein 1 alpha (MIP-1alpha) (P < 0.05). Daptomycin 0-10 C-C motif chemokine ligand 3 Homo sapiens 138-177 20065062-3 2010 Daptomycin led to lower CSF concentrations of interleukin 1beta (IL-1beta), IL-10, IL-18, monocyte chemoattractant protein 1 (MCP-1), and macrophage inflammatory protein 1 alpha (MIP-1alpha) (P < 0.05). Daptomycin 0-10 C-C motif chemokine ligand 3 Homo sapiens 179-189 17852899-0 2008 Long-term use of daptomycin for MRSA osteomyelitis and joint infection. Daptomycin 17-27 solute carrier family 9 member A6 Homo sapiens 32-36 19744978-12 2009 Daptomycin was bactericidal against hVISA strains. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 36-41 17954690-7 2008 Moreover, the cross-resistance to hNP-1 and tPMP-1 may also impact the capacity of these daptomycin-resistant organisms to be cleared from sites of infection, particularly endovascular foci. Daptomycin 89-99 neuronal pentraxin 1 Homo sapiens 34-39 19364845-3 2009 The daptomycin MIC and the minimum bactericidal concentration in logarithmic phase and stationary growth phase of MRSA were 0.625, 0.625, and 20 microg/ml, respectively. Daptomycin 4-14 solute carrier family 9 member A6 Homo sapiens 114-118 19364845-4 2009 In time-kill studies, daptomycin showed rapid and concentration-dependent killing of MRSA in stationary growth phase. Daptomycin 22-32 solute carrier family 9 member A6 Homo sapiens 85-89 19364845-6 2009 In treatment studies, daptomycin alone reduced the planktonic MRSA counts by 0.3 log(10) CFU/ml, whereas in combination with rifampin, a reduction in the counts of >6 log(10) CFU/ml was observed. Daptomycin 22-32 solute carrier family 9 member A6 Homo sapiens 62-66 19364845-9 2009 In addition, daptomycin at a high dose (30 mg/kg) completely prevented the emergence of rifampin resistance in planktonic and adherent MRSA cells. Daptomycin 13-23 solute carrier family 9 member A6 Homo sapiens 135-139 19364845-10 2009 Daptomycin at a high dose, corresponding to 6 mg/kg in humans, in combination with rifampin showed the highest activity against planktonic and adherent MRSA. Daptomycin 0-10 solute carrier family 9 member A6 Homo sapiens 152-156 19364845-11 2009 Daptomycin plus rifampin is a promising treatment option for implant-associated MRSA infections. Daptomycin 0-10 solute carrier family 9 member A6 Homo sapiens 80-84 19838095-8 2009 The thickness of bacterial cell-wall recognized in h-VISA strains can represent a physical and electrical barrier to reach both the vancomycin and daptomycin target site. Daptomycin 147-157 mitochondrial antiviral signaling protein Homo sapiens 53-57 18984644-9 2009 Daptomycin was bactericidal against both MRSA and hVISA isolates, although the rate of kill was slower against hVISA. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 50-55 18984644-9 2009 Daptomycin was bactericidal against both MRSA and hVISA isolates, although the rate of kill was slower against hVISA. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 111-116 18984644-10 2009 CONCLUSIONS: Overall, daptomycin achieved rapid and effective kill against both MRSA and hVISA while vancomycin displayed slow and minimal kill against MRSA and minimal-to-no activity against hVISA, regardless of high dose exposure. Daptomycin 22-32 mitochondrial antiviral signaling protein Homo sapiens 89-94 18180613-0 2008 Interaction of daptomycin with two recombinant thromboplastin reagents leads to falsely prolonged patient prothrombin time/International Normalized Ratio results. Daptomycin 15-25 coagulation factor II, thrombin Homo sapiens 106-117 18180613-3 2008 The present study evaluated the effect of daptomycin on measured prothrombin time using commercially available thromboplastin reagent kits commonly used in the United States. Daptomycin 42-52 coagulation factor II, thrombin Homo sapiens 65-76 18180613-7 2008 Triplicate assays of the prothrombin time were performed on the daptomycin-spiked plasma samples using each of the 30 kits. Daptomycin 64-74 coagulation factor II, thrombin Homo sapiens 25-36 18180613-10 2008 Addition of daptomycin to human plasma samples dose-dependently prolonged measured prothrombin times when two recombinant thromboplastin reagents were utilized. Daptomycin 12-22 coagulation factor II, thrombin Homo sapiens 83-94 18180613-14 2008 Prolonged International Normalized Ratio patient values were an artifact caused by the interaction of daptomycin with the in-vitro prothrombin time test reagent; an in-vivo anticoagulant effect was not observed. Daptomycin 102-112 coagulation factor II, thrombin Homo sapiens 131-142 18180613-15 2008 Healthcare providers should consider a possible drug-laboratory test interaction if prolonged prothrombin time or elevated International Normalized Ratio values are observed in patients receiving daptomycin. Daptomycin 196-206 coagulation factor II, thrombin Homo sapiens 94-105 18473888-6 2008 The information on the organization and expression of the NRPS and other genes has been exploited to generate combinatorial libraries of hybrid lipopeptide antibiotics related to daptomycin, including several compounds with very good antibacterial activities. Daptomycin 179-189 AT695_RS02960 Staphylococcus aureus 58-62 17371820-6 2007 Daptomycin cleared the bacteria more efficiently from the CSF than ceftriaxone within 2 h after the initiation of therapy (log(10) 3.6 +/- 1.0 and log(10) 6.3 +/- 1.4 CFU/ml, respectively; P < 0.02); reduced the inflammatory host reaction, as assessed by the matrix metalloproteinase-9 concentration in CSF 40 h after infection (P < 0.005); and prevented the development of cortical injury (cortical injury present in 0/30 and 7/28 animals, respectively; P < 0.004). Daptomycin 0-10 matrix metallopeptidase 9 Rattus norvegicus 262-288 17548493-0 2007 Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells. Daptomycin 70-80 PGP Canis lupus familiaris 131-145 17548493-0 2007 Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells. Daptomycin 70-80 ATP binding cassette subfamily B member 1 Homo sapiens 147-151 17548493-0 2007 Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells. Daptomycin 70-80 GLI family zinc finger 2 Homo sapiens 181-186 17548493-2 2007 We have examined its effect on the modulation of the intracellular accumulation and activity of daptomycin towards phagocytized Staphylococcus aureus (ATCC 25923) in human THP-1 macrophages, in comparison with MDCK epithelial cells (wild type and MDCK-MDR1 overexpressing P-gp; the bulk of the protein was immunodetected at the surface of all three cell types). Daptomycin 96-106 GLI family zinc finger 2 Homo sapiens 172-177 17548493-2 2007 We have examined its effect on the modulation of the intracellular accumulation and activity of daptomycin towards phagocytized Staphylococcus aureus (ATCC 25923) in human THP-1 macrophages, in comparison with MDCK epithelial cells (wild type and MDCK-MDR1 overexpressing P-gp; the bulk of the protein was immunodetected at the surface of all three cell types). Daptomycin 96-106 ATP binding cassette subfamily B member 1 Canis lupus familiaris 252-256 17548493-2 2007 We have examined its effect on the modulation of the intracellular accumulation and activity of daptomycin towards phagocytized Staphylococcus aureus (ATCC 25923) in human THP-1 macrophages, in comparison with MDCK epithelial cells (wild type and MDCK-MDR1 overexpressing P-gp; the bulk of the protein was immunodetected at the surface of all three cell types). Daptomycin 96-106 PGP Canis lupus familiaris 272-276 17548493-3 2007 Daptomycin displayed concentration-dependent intracellular activity (Hill equation pattern) in THP-1 and MDCK cells with (i) 50% effective drug extracellular concentration (EC(50); relative potency) and static concentrations at 9 to 10 times the MIC and (ii) maximal efficacy (E(max); CFU decrease at infinite extracellular drug concentration) at 1.6 to 2 log compared to that of the postphagocytosis inoculum. Daptomycin 0-10 GLI family zinc finger 2 Homo sapiens 95-100 17548493-7 2007 We conclude that daptomycin is subject to efflux from THP-1 macrophages and MDCK cells by P-gp, which reduces its intracellular activity against phagocytized S. aureus. Daptomycin 17-27 GLI family zinc finger 2 Homo sapiens 54-59 17548493-7 2007 We conclude that daptomycin is subject to efflux from THP-1 macrophages and MDCK cells by P-gp, which reduces its intracellular activity against phagocytized S. aureus. Daptomycin 17-27 PGP Canis lupus familiaris 90-94 17588430-5 2007 The patient had MRSA sepsis develop resistant to conventional therapy, which was successfully treated with daptomycin. Daptomycin 107-117 solute carrier family 9 member A6 Homo sapiens 16-20 17531446-7 2007 Daptomycin MIC and MBC values were slightly higher for the hVISA isolates compared with WT-MRSA, with MBC/MIC ratios of only 1-2 for both groups. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 59-64 17531446-10 2007 Daptomycin was demonstrated to have excellent in vitro activity when tested against Gram-positive isolates collected from Asia-Pacific countries, including hVISA strains. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 156-161 34694870-6 2022 Furthermore, pre-conditioning to this strain-pair to DAP +/- Fosfo sensitized these organisms to killing by the human host defense peptide, LL37. Daptomycin 53-56 cathelicidin antimicrobial peptide Homo sapiens 140-144 16546333-5 2006 Daptomycin macromolecular conjugates were characterized by drug loading, drug release, and binding affinity for fibrinogen using HPLC analysis and surface plasmon resonance. Daptomycin 0-10 fibrinogen beta chain Homo sapiens 112-122 15681583-0 2005 In vivo synergy of daptomycin plus a penicillin agent for MRSA? Daptomycin 19-29 solute carrier family 9 member A6 Homo sapiens 58-62 12775678-3 2003 In vitro elimination of strain Rev1 in the presence of 50% tissue cage fluid was more rapid with daptomycin 4 mg/L compared with vancomycin. Daptomycin 97-107 REV1, DNA directed polymerase Rattus norvegicus 31-35 16801409-3 2006 All MRSA-WT and hVISA strains were inhibited by < or = 1 microg/ml of daptomycin, while the VISA strains showed slightly higher daptomycin MICs (range, 0.5 to 4 microg/ml). Daptomycin 73-83 mitochondrial antiviral signaling protein Homo sapiens 16-21 16801409-3 2006 All MRSA-WT and hVISA strains were inhibited by < or = 1 microg/ml of daptomycin, while the VISA strains showed slightly higher daptomycin MICs (range, 0.5 to 4 microg/ml). Daptomycin 73-83 mitochondrial antiviral signaling protein Homo sapiens 17-21 18360590-6 2006 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors should be stopped in patients on daptomycin. Daptomycin 102-112 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-57 15535984-1 2004 Two in vitro studies assessed the potential of daptomycin (Cubicin), a newly marketed antibiotic, to affect the cytochrome P450 (CYP450) isoforms in primary cultured human hepatocytes. Daptomycin 47-57 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 112-127 15535984-1 2004 Two in vitro studies assessed the potential of daptomycin (Cubicin), a newly marketed antibiotic, to affect the cytochrome P450 (CYP450) isoforms in primary cultured human hepatocytes. Daptomycin 47-57 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 129-135 9585574-0 1998 Modulation of phospholipase A2 activity by aminoglycosides and daptomycin: a Fourier transform infrared spectroscopic study. Daptomycin 63-73 phospholipase A2 group IB Homo sapiens 14-30 9585574-4 1998 In the present study, Fourier transform infrared spectroscopy (FTIR) has been used to monitor the hydrolysis of phosphatidylcholine by phospholipase A2 (PLA2) from Naja mocambique mocambique venom in the presence of various aminoglycosides and/or daptomycin. Daptomycin 247-257 phospholipase A2 group IB Homo sapiens 135-151 9585574-4 1998 In the present study, Fourier transform infrared spectroscopy (FTIR) has been used to monitor the hydrolysis of phosphatidylcholine by phospholipase A2 (PLA2) from Naja mocambique mocambique venom in the presence of various aminoglycosides and/or daptomycin. Daptomycin 247-257 phospholipase A2 group IB Homo sapiens 153-157 9585574-10 1998 The most drastic change occurred with gentamicin, which was the most inhibitory aminoglycoside when used alone but worked synergistically with daptomycin to yield the most dramatic activation of PLA2. Daptomycin 143-153 phospholipase A2 group IB Homo sapiens 195-199 34643345-2 2021 We report on a premature infant who developed hepatotoxicity as an adverse drug reaction after the administration of daptomycin 6 mg per kg per dose every 12 h. The patient had an unexpectedly sharp rise of alanine aminotransaminase, prothrombin time and international normalised ratio on the second day following daptomycin administration. Daptomycin 117-127 coagulation factor II, thrombin Homo sapiens 234-245 34618036-0 2021 Impact of PrsA on membrane lipid composition during daptomycin-resistance-mediated beta-lactam sensitization in clinical MRSA strains. Daptomycin 52-62 glutaredoxin 5 Homo sapiens 10-14 34618036-5 2021 OBJECTIVES: We aimed: (i) to investigate the combined effects of daptomycin and oxacillin on the lipid composition of the cellular membrane of both daptomycin-resistant and -susceptible MRSA strains; and (ii) to assess the involvement of the post-translocational protein PrsA, which plays an important role in oxacillin resistance in MRSA, in membrane lipid composition and remodelling during daptomycin resistance/beta-lactam sensitization. Daptomycin 65-75 glutaredoxin 5 Homo sapiens 271-275 34618036-5 2021 OBJECTIVES: We aimed: (i) to investigate the combined effects of daptomycin and oxacillin on the lipid composition of the cellular membrane of both daptomycin-resistant and -susceptible MRSA strains; and (ii) to assess the involvement of the post-translocational protein PrsA, which plays an important role in oxacillin resistance in MRSA, in membrane lipid composition and remodelling during daptomycin resistance/beta-lactam sensitization. Daptomycin 393-403 glutaredoxin 5 Homo sapiens 271-275 34618036-6 2021 RESULTS: The combination of microbiological and biochemical studies, with fluorescence microscopy using lipid probes, showed that the lipid composition and surface charge of the daptomycin-resistant cells exposed to daptomycin/oxacillin were dependent on antibiotic concentration and directly associated with PrsA, which influenced cardiolipin remodelling/relocation. Daptomycin 178-188 glutaredoxin 5 Homo sapiens 309-313 34618036-6 2021 RESULTS: The combination of microbiological and biochemical studies, with fluorescence microscopy using lipid probes, showed that the lipid composition and surface charge of the daptomycin-resistant cells exposed to daptomycin/oxacillin were dependent on antibiotic concentration and directly associated with PrsA, which influenced cardiolipin remodelling/relocation. Daptomycin 216-226 glutaredoxin 5 Homo sapiens 309-313 34618036-7 2021 CONCLUSIONS: Our findings show that PrsA, in addition to its post-transcriptional role in the maturation of PBP 2a, is a key mediator of cell membrane remodelling connected to the see-saw effect and may have a key role in the resensitization of daptomycin-resistant strains to beta-lactams, such as oxacillin. Daptomycin 245-255 glutaredoxin 5 Homo sapiens 36-40 34643345-2 2021 We report on a premature infant who developed hepatotoxicity as an adverse drug reaction after the administration of daptomycin 6 mg per kg per dose every 12 h. The patient had an unexpectedly sharp rise of alanine aminotransaminase, prothrombin time and international normalised ratio on the second day following daptomycin administration. Daptomycin 314-324 coagulation factor II, thrombin Homo sapiens 234-245 34381269-3 2021 The primary outcome was the proportion of patients with a documented infusion-related reaction (IRR) to daptomycin. Daptomycin 104-114 insulin receptor related receptor Homo sapiens 96-99 34253886-4 2021 Engagement of RPS19 by DAP was shown by CETSA and ITDRFCETSA assays, and knocking down of RPS19 with siRNA increased the potency of DAP in MCF7 cells. Daptomycin 23-26 ribosomal protein S19 Homo sapiens 14-19 34253886-0 2021 Daptomycin suppresses tumor migration and angiogenesis via binding to ribosomal protein S19 in humans. Daptomycin 0-10 ribosomal protein S19 Homo sapiens 70-91 34253886-1 2021 We have previously reported that daptomycin (DAP), a last resort antibiotic, binds to ribosomal protein S19 (RPS19) in humans and exhibits selective anti-cancer activity against MCF7 breast cancer cells. Daptomycin 33-43 ribosomal protein S19 Homo sapiens 86-107 34253886-1 2021 We have previously reported that daptomycin (DAP), a last resort antibiotic, binds to ribosomal protein S19 (RPS19) in humans and exhibits selective anti-cancer activity against MCF7 breast cancer cells. Daptomycin 33-43 ribosomal protein S19 Homo sapiens 109-114 34253886-1 2021 We have previously reported that daptomycin (DAP), a last resort antibiotic, binds to ribosomal protein S19 (RPS19) in humans and exhibits selective anti-cancer activity against MCF7 breast cancer cells. Daptomycin 45-48 ribosomal protein S19 Homo sapiens 86-107 34253886-1 2021 We have previously reported that daptomycin (DAP), a last resort antibiotic, binds to ribosomal protein S19 (RPS19) in humans and exhibits selective anti-cancer activity against MCF7 breast cancer cells. Daptomycin 45-48 ribosomal protein S19 Homo sapiens 109-114 34253886-4 2021 Engagement of RPS19 by DAP was shown by CETSA and ITDRFCETSA assays, and knocking down of RPS19 with siRNA increased the potency of DAP in MCF7 cells. Daptomycin 132-135 ribosomal protein S19 Homo sapiens 14-19 34253886-4 2021 Engagement of RPS19 by DAP was shown by CETSA and ITDRFCETSA assays, and knocking down of RPS19 with siRNA increased the potency of DAP in MCF7 cells. Daptomycin 132-135 ribosomal protein S19 Homo sapiens 90-95 34253886-5 2021 In addition, DAP suppressed the secretion of VEGF in cancer cells and thereby inhibited cell migration. Daptomycin 13-16 vascular endothelial growth factor A Homo sapiens 45-49 34253886-6 2021 Collectively, these data provide an outline of the underlying mechanism of how DAP exhibits anti-cancer activity and suggests that RPS19 could be a promising target for the development of new anticancer drugs. Daptomycin 79-82 ribosomal protein S19 Homo sapiens 131-136 35495706-9 2022 However, in SC1762-D (i.e., daptomycin-resistant mutant of SC1762), all vanA cluster genes except the vanX gene were obviously downregulated. Daptomycin 28-38 VanX protein Enterococcus faecium 102-106 34296627-9 2021 The response of the cytokines TNFalpha, IL-6, and IL-10 was measured in vitro using murine peritoneal macrophages stimulated with LPS and VAN or DMC. Daptomycin 145-148 interleukin 10 Mus musculus 50-55 35418571-6 2022 In contrast, mucin sedimentation profiles were largely unaltered after treatment with daptomycin or polymyxin B. Daptomycin 86-96 LOC100508689 Homo sapiens 13-18 33508054-3 2021 During the synthesis of daptomycin, this side reaction was accompanied by intractable peptide decomposition, which resulted in a low yield of Dap and a 4-quinolone containing peptide. Daptomycin 24-34 death associated protein Homo sapiens 142-145 34013390-1 2021 PURPOSE: This study evaluated the population pharmacokinetics of daptomycin in nonobese elderly patients with hypoalbuminemia and chronic kidney disease (CKD) using the glomerular filtration rate estimated from cystatin C (eGFRcys) and estimated its optimal dose. Daptomycin 65-75 cystatin C Homo sapiens 211-221 35107993-3 2022 Teicoplanin-responsive T-cells were CD8+, HLA class I-restricted, and cross-reacted with the lipoglycopeptide daptomycin in proliferation and cytokine/cytolytic molecule (granzyme B, Perforin, and FasL) release assays. Daptomycin 110-120 CD8a molecule Homo sapiens 36-39 35107993-3 2022 Teicoplanin-responsive T-cells were CD8+, HLA class I-restricted, and cross-reacted with the lipoglycopeptide daptomycin in proliferation and cytokine/cytolytic molecule (granzyme B, Perforin, and FasL) release assays. Daptomycin 110-120 granzyme B Homo sapiens 171-181 35107993-3 2022 Teicoplanin-responsive T-cells were CD8+, HLA class I-restricted, and cross-reacted with the lipoglycopeptide daptomycin in proliferation and cytokine/cytolytic molecule (granzyme B, Perforin, and FasL) release assays. Daptomycin 110-120 Fas ligand Homo sapiens 197-201 35602976-5 2022 Notably, we discovered that daptomycin, an FDA-approved antibiotic, has a prominent CTSL inhibitory effect and can inhibit SARS-CoV-2 pseudovirus infection. Daptomycin 28-38 cathepsin L Homo sapiens 84-88 3038001-1 1987 LY146032, a new lipopeptide, was found to have a spectrum of gram-positive antimicrobial activity that includes activity against staphylococci (methicillin susceptible and resistant), beta-hemolytic Streptococcus spp., pneumococci, viridans group Streptococcus spp., anaerobic gram-positive cocci, Clostridium spp., and enterococci. Daptomycin 0-8 histocompatibility minor 13 Homo sapiens 213-216 3038001-1 1987 LY146032, a new lipopeptide, was found to have a spectrum of gram-positive antimicrobial activity that includes activity against staphylococci (methicillin susceptible and resistant), beta-hemolytic Streptococcus spp., pneumococci, viridans group Streptococcus spp., anaerobic gram-positive cocci, Clostridium spp., and enterococci. Daptomycin 0-8 histocompatibility minor 13 Homo sapiens 261-264 3038001-1 1987 LY146032, a new lipopeptide, was found to have a spectrum of gram-positive antimicrobial activity that includes activity against staphylococci (methicillin susceptible and resistant), beta-hemolytic Streptococcus spp., pneumococci, viridans group Streptococcus spp., anaerobic gram-positive cocci, Clostridium spp., and enterococci. Daptomycin 0-8 histocompatibility minor 13 Homo sapiens 261-264 3036499-1 1987 Agar dilution and time-kill techniques were used to assess the in vitro activity of LY146032 and several other antibacterial agents against Corynebacterium spp. Daptomycin 84-92 histocompatibility minor 13 Homo sapiens 156-159 33946290-0 2021 Catalase Protects Biofilm of Staphylococcus aureus against Daptomycin Activity. Daptomycin 59-69 AT695_RS10915 Staphylococcus aureus 0-8 33946290-8 2021 The bacterial survival was higher and the amount of ROS was lower in the wild type than in the catalase deficient biofilm, demonstrating a protective effect of catalase against daptomycin. Daptomycin 177-187 AT695_RS10915 Staphylococcus aureus 95-103 33642512-4 2021 Anti-DAP antibody was obtained by immunizing mice with an antigen conjugated with mercaptosuccinyl bovine serum albumin using N-(4-maleimidobutyryloxy) succinimide as a heterobifunctional coupling agent. Daptomycin 5-8 albumin Mus musculus 106-119 33609718-2 2021 Combination therapy with daptomycin and ceftaroline (DAP+CPT) represents a novel therapeutic approach to MRSA BSI due to synergistic bactericidal activity. Daptomycin 25-35 death associated protein Homo sapiens 53-56 32123664-8 2020 The patient was treated with two weeks of IV ceftriaxone and was discharged with plans to complete a six-week course of IV daptomycin due to MRSA bacteremia. Daptomycin 123-133 solute carrier family 9 member A6 Homo sapiens 141-145 32581153-9 2020 A necroptotic pathway seemed to be involved because phosphorylated mixed lineage kinase domain-like protein expression was enhanced following daptomycin exposure, which was significantly enhanced under hypoxic conditions. Daptomycin 142-152 mixed lineage kinase domain like pseudokinase Homo sapiens 67-107 31559654-6 2020 We further demonstrate that this phenotype is coincident with the acquisition of specific point mutations in the cardiolipin synthase gene cls2, and, partly, in the bifunctional lysylphosphatidylglycerol flippase/synthetase gene mprF, which are genes that are often mutated in clinical daptomycin-resistant strains. Daptomycin 286-296 AT695_RS07090 Staphylococcus aureus 113-133 31938716-5 2020 SOC was empiric treatment with vancomycin or daptomycin and any subsequent combination antibiotic(s), except for DAP-CPT. Daptomycin 45-55 UBX domain protein 11 Homo sapiens 0-3 31651331-10 2019 CONCLUSIONS: Although the effectiveness of LZD and DAP was equivalent in terms of infection control rates for refractory PJIs with gram-positive pathogens, DAP therapy significantly decreased CRP levels and caused fewer adverse events than LZD treatment. Daptomycin 156-159 C-reactive protein Homo sapiens 192-195 31818937-6 2019 The N-terminal domain of LiaX binds daptomycin and AMPs (such as human LL-37) and functions as an extracellular sentinel that activates the cell envelope stress response. Daptomycin 36-46 cathelicidin antimicrobial peptide Homo sapiens 71-76 31795437-8 2019 At MIC <= 2 mug/mL, a daptomycin dosage of 12 mg/kg/day achieved the PTA target of survival and microbiological response at the first 24 h time point and steady state. Daptomycin 22-32 CD99 molecule (Xg blood group) Homo sapiens 3-11 31505641-9 2019 MRSA were most susceptible to ceftobiprole, linezolid and telavancin (100%), daptomycin (99.9%), vancomycin (99.8%) and tigecycline (99.2%). Daptomycin 77-87 solute carrier family 9 member A6 Homo sapiens 0-4 30938438-3 2019 Here, using a laboratory strain of Enterococcus faecalis, we developed a novel Caenorhabditis elegans model of daptomycin therapy and showed that disrupting LiaR-mediated cell membrane adaptation restores the in vivo activity of daptomycin. Daptomycin 111-121 ankyrin repeat domain 54 Homo sapiens 157-161 30938438-3 2019 Here, using a laboratory strain of Enterococcus faecalis, we developed a novel Caenorhabditis elegans model of daptomycin therapy and showed that disrupting LiaR-mediated cell membrane adaptation restores the in vivo activity of daptomycin. Daptomycin 229-239 ankyrin repeat domain 54 Homo sapiens 157-161 30938438-4 2019 The LiaR effect was also seen in a clinical strain of daptomycin-resistant Enterococcus faecium, using a murine model of peritonitis. Daptomycin 54-64 ankyrin repeat domain 54 Homo sapiens 4-8 31031170-4 2019 Experimental evolution in the presence of LCA yielded mutations in the essential two-component kinase yycG/walK and three-component response regulator liaR that locked VRE in diplococcal mode, impaired biofilm formation, and increased susceptibility to the antibiotic daptomycin. Daptomycin 268-278 ankyrin repeat domain 54 Homo sapiens 151-155 30629193-0 2019 Genetic polymorphisms of ABCB1 (P-glycoprotein) as a covariate influencing daptomycin pharmacokinetics: a population analysis in patients with bone and joint infection. Daptomycin 75-85 ATP binding cassette subfamily B member 1 Homo sapiens 25-30 30629193-0 2019 Genetic polymorphisms of ABCB1 (P-glycoprotein) as a covariate influencing daptomycin pharmacokinetics: a population analysis in patients with bone and joint infection. Daptomycin 75-85 ATP binding cassette subfamily B member 1 Homo sapiens 32-46 30629193-2 2019 Gene polymorphism of ABCB1, the gene encoding P-glycoprotein (P-gp), may influence daptomycin pharmacokinetics (PK). Daptomycin 83-93 ATP binding cassette subfamily B member 1 Homo sapiens 21-26 30629193-2 2019 Gene polymorphism of ABCB1, the gene encoding P-glycoprotein (P-gp), may influence daptomycin pharmacokinetics (PK). Daptomycin 83-93 ATP binding cassette subfamily B member 1 Homo sapiens 46-60 30629193-2 2019 Gene polymorphism of ABCB1, the gene encoding P-glycoprotein (P-gp), may influence daptomycin pharmacokinetics (PK). Daptomycin 83-93 ATP binding cassette subfamily B member 1 Homo sapiens 62-66 30629193-10 2019 Daptomycin central V (V1) was allometrically scaled to body weight and was 25% lower in patients with homozygous CGC ABCB1 haplotype than in patients with any other genotype. Daptomycin 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 117-122 29130946-6 2018 DAP loading-dose regimen iii showed greater antimicrobial activity against MRSA with MIC 1 mg/L than nonloading regimen iv (-3.10 +- 0.63 vs. -0.71 +- 0.34 log10 CFU; p < 0.01). Daptomycin 0-3 growth differentiation factor 15 Mus musculus 85-90 30726929-0 2019 Genomic characterization of inpatient evolution of MRSA resistant to daptomycin, vancomycin and ceftaroline. Daptomycin 69-79 solute carrier family 9 member A6 Homo sapiens 51-55 30663951-0 2019 Utilizing genomic analyses to investigate the first outbreak of vanA vancomycin-resistant Enterococcus in Australia with emergence of daptomycin non-susceptibility. Daptomycin 134-144 Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase Enterococcus faecium 64-68 30538064-4 2019 Two peptides were prepared in which the threonine4 residue in the active daptomycin analog, Dap-K6-E12-W13, was replaced with (2S,3R)-diaminobutyric acid ((2S,3R)-DABA) or its epimer (2S,3S-DABA) converting the ring-closing ester bond to an amide bond. Daptomycin 73-83 death associated protein Homo sapiens 92-95 30538064-7 2019 ent-Dap-K6-E12-W13 was found to be at least 133-fold less active than Dap-K6-E12-W13, indicating that a chiral interaction with a chiral target is essential to daptomycin"s activity. Daptomycin 160-170 death associated protein Homo sapiens 4-7 30538064-7 2019 ent-Dap-K6-E12-W13 was found to be at least 133-fold less active than Dap-K6-E12-W13, indicating that a chiral interaction with a chiral target is essential to daptomycin"s activity. Daptomycin 160-170 death associated protein Homo sapiens 70-73 30224525-1 2018 We evaluated the effects of rifampin coadministration and MDR1 single nucleotide polymorphisms on the disposition of daptomycin in twelve healthy adults. Daptomycin 117-127 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 29718242-7 2018 Results: Single mutations in snoF, hmp1, sspA, rimP, hepT, rsh, map1 and amaP had only a modest impact on the daptomycin MIC (<=2-fold). Daptomycin 110-120 Glutamyl endopeptidase precursor, serine proteinase SspA Staphylococcus aureus 41-45 29329389-9 2018 Conclusions: DAP12 was the most successful strategy against IE due to a WT E. faecium strain (daptomycin MIC = 2 mg/L). Daptomycin 94-104 transmembrane immune signaling adaptor TYROBP Homo sapiens 13-18 29293268-5 2018 This approach was used to synthesize a series of analogs in which each position of Dap-E12-W13, a relatively active daptomycin analog, was individually substituted by alanine. Daptomycin 116-126 death associated protein Homo sapiens 83-86 29293268-7 2018 We also found that the daptomycin analog, Dap-K6-E12-W13, exhibits in vitro activity approaching that of daptomycin at physiological Ca2+ concentration. Daptomycin 23-33 death associated protein Homo sapiens 42-45 29293268-7 2018 We also found that the daptomycin analog, Dap-K6-E12-W13, exhibits in vitro activity approaching that of daptomycin at physiological Ca2+ concentration. Daptomycin 105-115 death associated protein Homo sapiens 42-45 26452467-5 2017 TNF-alpha levels were significantly higher after ceftriaxone administration than in both daptomycin groups. Daptomycin 89-99 tumor necrosis factor Oryctolagus cuniculus 0-9 29179737-0 2017 Dose-dependent effect of daptomycin on the artificial prolongation of prothrombin time in coagulation abnormalities: in vitro verification. Daptomycin 25-35 coagulation factor II, thrombin Homo sapiens 70-81 29179737-1 2017 BACKGROUND: Several studies have reported that daptomycin induced artificial prolongation of prothrombin time (PT) in some test reagents, particularly in warfarin users. Daptomycin 47-57 coagulation factor II, thrombin Homo sapiens 93-104 29170657-1 2017 Daptomycin-resistant (DAP-R) Staphylococcus aureus strains are well documented, but have not been reported in China. Daptomycin 0-10 death associated protein Homo sapiens 22-25 26452467-8 2017 CONCLUSION: CSF TNF-alpha levels were significantly lower in rabbits treated with daptomycin than in rabbits treated with ceftriaxone. Daptomycin 82-92 tumor necrosis factor Oryctolagus cuniculus 16-25 26452467-10 2017 The use of daptomycin plus dexamethasone achieved a significantly larger reduction in CSF TNF-alpha levels. Daptomycin 11-21 tumor necrosis factor Oryctolagus cuniculus 90-99 28680364-0 2016 Daptomycin, a last-resort antibiotic, binds ribosomal protein S19 in humans. Daptomycin 0-10 ribosomal protein S19 Homo sapiens 44-65 28680364-7 2016 The unbiased interrogation of human cDNA libraries, displayed on bacteriophage T7, revealed a single human target of daptomycin; ribosomal protein S19. Daptomycin 117-127 ribosomal protein S19 Homo sapiens 129-150 28680364-8 2016 Using a drug affinity responsive target stability (DARTS) assay in vitro, we show that daptomycin stabilizes RPS19 toward pronase. Daptomycin 87-97 ribosomal protein S19 Homo sapiens 109-114 28680364-9 2016 Fluorescently labeled daptomycin stained specific structures in HeLa cells and co-localized with a RPS19 antibody. Daptomycin 22-32 ribosomal protein S19 Homo sapiens 99-104 28680364-10 2016 CONCLUSION: This study provides, for the first time, a human protein target of daptomycin and identifies RPS19 as a possible anticancer drug target for the development of new pharmacological applications and research. Daptomycin 79-89 ribosomal protein S19 Homo sapiens 105-110 27628437-8 2017 CONCLUSIONS: Q24 h dosing of daptomycin up to 12 mg kg-1 provides comparable drug exposure in patients on CVVHD and in those with CrCl >= 30 ml min-1 . Daptomycin 29-39 CD59 molecule (CD59 blood group) Homo sapiens 147-152 28399872-0 2017 Dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in vivo clinical study. Daptomycin 82-92 coagulation factor II, thrombin Homo sapiens 42-53 28399872-1 2017 BACKGROUND: Daptomycin has been reported to cause artificial prolongation of prothrombin time (PT) by interacting with some test reagents of PT. Daptomycin 12-22 coagulation factor II, thrombin Homo sapiens 77-88 27060578-0 2016 False Prolongation of Prothrombin Time in the Presence of a High Blood Concentration of Daptomycin. Daptomycin 88-98 coagulation factor II, thrombin Homo sapiens 22-33 27795377-8 2017 DAP-OXA-mediated effects resulted in cell wall perturbations, including changes in peptidoglycan insertion, penicillin-binding protein 2 (PBP 2) delocalization, and reduced membrane amounts of PBP 2a, despite the increased transcription of mecA through mec regulatory elements. Daptomycin 0-3 AT695_RS10295 Staphylococcus aureus 108-136 27795377-8 2017 DAP-OXA-mediated effects resulted in cell wall perturbations, including changes in peptidoglycan insertion, penicillin-binding protein 2 (PBP 2) delocalization, and reduced membrane amounts of PBP 2a, despite the increased transcription of mecA through mec regulatory elements. Daptomycin 0-3 AT695_RS10295 Staphylococcus aureus 138-143 27060578-1 2016 Prothrombin time (PT) can reportedly be falsely prolonged by the antimicrobial drug daptomycin (DAP), and concomitant use of phosphatidylglycerol (PG). Daptomycin 84-94 coagulation factor II, thrombin Homo sapiens 0-11 27060578-1 2016 Prothrombin time (PT) can reportedly be falsely prolonged by the antimicrobial drug daptomycin (DAP), and concomitant use of phosphatidylglycerol (PG). Daptomycin 96-99 coagulation factor II, thrombin Homo sapiens 0-11 26258318-9 2015 Gram-positive related infections and MRSA infections occurred in 1(1.18%)/0(0%) of Vancomycin patients and 9 (9.68%)/1 (1.08%) of Daptomycin patients, respectively (P < 0.02 and P = 1.00). Daptomycin 130-140 solute carrier family 9 member A6 Homo sapiens 37-41 26320398-11 2016 Compared with vancomycin-susceptible S. aureus, hVISA and VISA isolates were less susceptible to ciprofloxacin, clindamycin, daptomycin, gentamicin, rifampin, and trimethoprim/sulfamethoxazole, and are thus, more likely to have SCCmec II or III element. Daptomycin 125-135 mitochondrial antiviral signaling protein Homo sapiens 48-53 26320398-11 2016 Compared with vancomycin-susceptible S. aureus, hVISA and VISA isolates were less susceptible to ciprofloxacin, clindamycin, daptomycin, gentamicin, rifampin, and trimethoprim/sulfamethoxazole, and are thus, more likely to have SCCmec II or III element. Daptomycin 125-135 mitochondrial antiviral signaling protein Homo sapiens 49-53 27441208-4 2016 In this study, we used Staphylococcus aureus (S. aureus) as a proof-of-principle ESKAPE pathogen to demonstrate that an appropriate antibiotic (daptomycin) can be incorporated into polydopamine-coated gold nanocages (AuNC@PDA) and that daptomycin-loaded AuNC@PDA can be conjugated to antibodies targeting a species-specific surface protein (staphylococcal protein A; Spa) as a means of achieving selective delivery of the nanoconstructs directly to the bacterial cell surface. Daptomycin 144-154 surfactant protein A2 Homo sapiens 367-370 31156816-3 2016 Methods: Reconstituted solution of daptomycin was added to a total of nine PD bags to obtain a concentration of 20 mg/L and stored at 1 of 3 different temperatures: 4 or 25 C for up to 168 h or 37 C for up to 48 h. Stabilities were determined by visual inspection, pH measurement and high-performance liquid chromatography. Daptomycin 35-45 olfactory receptor family 13 subfamily C member 7 (gene/pseudogene) Homo sapiens 191-198 26485536-5 2016 When the daptomycin dodecylamine complex (DAP/DOA) was dissolved in a formulation containing 35% Dermofeel MCT, 30% Capmul MCM and 35% Cremophor RH40, a maximum payload of even 8.0% (w/w) corresponding to 5.5% pure daptomycin was achieved. Daptomycin 9-19 death associated protein Homo sapiens 42-45 26485536-9 2016 According to these results, SEDDS containing 8% DAP/DOA complex may be considered as a new potential oral delivery system for daptomycin. Daptomycin 126-136 death associated protein Homo sapiens 48-51 26968883-9 2016 Of these, mutation of fabF (encoding the fatty acid synthase) seemed to be partially responsible for the slow growth and ultrastructural features, including an abnormal intercellular substance, and for the daptomycin resistance of SCVs. Daptomycin 206-216 fatty acid synthase Homo sapiens 41-60 26369959-0 2015 Deletion of liaR Reverses Daptomycin Resistance in Enterococcus faecium Independent of the Genetic Background. Daptomycin 26-36 ankyrin repeat domain 54 Homo sapiens 12-16 26369959-2 2015 Indeed, deletion of the gene encoding the response regulator LiaR in a clinical strain of Enterococcus faecalis reversed DAP resistance (DAP-R) and produced a strain hypersusceptible to antimicrobial peptides. Daptomycin 121-124 ankyrin repeat domain 54 Homo sapiens 61-65 26369959-2 2015 Indeed, deletion of the gene encoding the response regulator LiaR in a clinical strain of Enterococcus faecalis reversed DAP resistance (DAP-R) and produced a strain hypersusceptible to antimicrobial peptides. Daptomycin 137-140 ankyrin repeat domain 54 Homo sapiens 61-65 26369959-4 2015 Deletion of liaR in DAP-R E. faecium R446F (DAP MIC of 16 mug/ml) and R497F (MIC of 24 mug/ml; harboring changes in LiaRS) strains fully reversed resistance (DAP MICs decreasing to 0.25 and 0.094 mug/ml, respectively). Daptomycin 20-23 ankyrin repeat domain 54 Homo sapiens 12-16 26369959-4 2015 Deletion of liaR in DAP-R E. faecium R446F (DAP MIC of 16 mug/ml) and R497F (MIC of 24 mug/ml; harboring changes in LiaRS) strains fully reversed resistance (DAP MICs decreasing to 0.25 and 0.094 mug/ml, respectively). Daptomycin 44-47 ankyrin repeat domain 54 Homo sapiens 12-16 26369959-6 2015 Furthermore, the liaR deletion derivatives of these two DAP-R strains exhibited increased binding of boron-dipyrromethene difluoride (BODIPY)-daptomycin, suggesting that high-level DAP-R mediated by LiaR in E. faecium involves repulsion of the calcium-DAP complex from the cell surface. Daptomycin 56-59 ankyrin repeat domain 54 Homo sapiens 17-21 26369959-6 2015 Furthermore, the liaR deletion derivatives of these two DAP-R strains exhibited increased binding of boron-dipyrromethene difluoride (BODIPY)-daptomycin, suggesting that high-level DAP-R mediated by LiaR in E. faecium involves repulsion of the calcium-DAP complex from the cell surface. Daptomycin 56-59 ankyrin repeat domain 54 Homo sapiens 199-203 26369959-6 2015 Furthermore, the liaR deletion derivatives of these two DAP-R strains exhibited increased binding of boron-dipyrromethene difluoride (BODIPY)-daptomycin, suggesting that high-level DAP-R mediated by LiaR in E. faecium involves repulsion of the calcium-DAP complex from the cell surface. Daptomycin 142-152 ankyrin repeat domain 54 Homo sapiens 17-21 26369959-7 2015 In DAP-tolerant strains HOU503F and HOU515F (DAP MICs within the susceptible range but bacteria not killed by DAP concentrations of 5x the MIC), deletion of liaR not only markedly decreased the DAP MICs (0.064 and 0.047 mug/ml, respectively) but also restored the bactericidal activity of DAP at concentrations as low as 4 mug/ml (achieved with human doses of 4 mg/kg). Daptomycin 3-6 ankyrin repeat domain 54 Homo sapiens 157-161 26369959-7 2015 In DAP-tolerant strains HOU503F and HOU515F (DAP MICs within the susceptible range but bacteria not killed by DAP concentrations of 5x the MIC), deletion of liaR not only markedly decreased the DAP MICs (0.064 and 0.047 mug/ml, respectively) but also restored the bactericidal activity of DAP at concentrations as low as 4 mug/ml (achieved with human doses of 4 mg/kg). Daptomycin 45-48 ankyrin repeat domain 54 Homo sapiens 157-161 26369959-7 2015 In DAP-tolerant strains HOU503F and HOU515F (DAP MICs within the susceptible range but bacteria not killed by DAP concentrations of 5x the MIC), deletion of liaR not only markedly decreased the DAP MICs (0.064 and 0.047 mug/ml, respectively) but also restored the bactericidal activity of DAP at concentrations as low as 4 mug/ml (achieved with human doses of 4 mg/kg). Daptomycin 45-48 ankyrin repeat domain 54 Homo sapiens 157-161 26369959-7 2015 In DAP-tolerant strains HOU503F and HOU515F (DAP MICs within the susceptible range but bacteria not killed by DAP concentrations of 5x the MIC), deletion of liaR not only markedly decreased the DAP MICs (0.064 and 0.047 mug/ml, respectively) but also restored the bactericidal activity of DAP at concentrations as low as 4 mug/ml (achieved with human doses of 4 mg/kg). Daptomycin 45-48 ankyrin repeat domain 54 Homo sapiens 157-161 26369959-7 2015 In DAP-tolerant strains HOU503F and HOU515F (DAP MICs within the susceptible range but bacteria not killed by DAP concentrations of 5x the MIC), deletion of liaR not only markedly decreased the DAP MICs (0.064 and 0.047 mug/ml, respectively) but also restored the bactericidal activity of DAP at concentrations as low as 4 mug/ml (achieved with human doses of 4 mg/kg). Daptomycin 45-48 ankyrin repeat domain 54 Homo sapiens 157-161 26369959-8 2015 Our results suggest that LiaR plays a relevant role in the enterococcal cell membrane adaptive response to antimicrobial peptides independent of the genetic background and emerges as an attractive target to restore the activity of DAP against multidrug-resistant strains. Daptomycin 231-234 ankyrin repeat domain 54 Homo sapiens 25-29 26520664-3 2015 Here we report a solid-phase synthesis of a daptomycin analog in which Thr4, 3-MeGlu12 and Kyn13 in daptomycin were replaced with Ser, Glu and Trp residues, respectively (Dap-S4-E12-W13). Daptomycin 44-54 death associated protein Homo sapiens 171-174 26520664-3 2015 Here we report a solid-phase synthesis of a daptomycin analog in which Thr4, 3-MeGlu12 and Kyn13 in daptomycin were replaced with Ser, Glu and Trp residues, respectively (Dap-S4-E12-W13). Daptomycin 100-110 death associated protein Homo sapiens 171-174 26430942-6 2015 Population analysis profile-area under curve analysis confirmed hVISA in 4.5% (9/198), 6.5% (8/123), and 6.7% (12/179) in respective years; 24% (7/29) of hVISA isolates were nonsusceptible to daptomycin. Daptomycin 192-202 mitochondrial antiviral signaling protein Homo sapiens 64-69 26430942-6 2015 Population analysis profile-area under curve analysis confirmed hVISA in 4.5% (9/198), 6.5% (8/123), and 6.7% (12/179) in respective years; 24% (7/29) of hVISA isolates were nonsusceptible to daptomycin. Daptomycin 192-202 mitochondrial antiviral signaling protein Homo sapiens 154-159 26169405-5 2015 The percentage of antibiotic measured in the dialysate after 4 h in the presence of mucin, relative to the amount without mucin, was 15% for colistin, 16% for polymyxin B, 19% for tobramycin, 52% for ciprofloxacin, and 78% for daptomycin. Daptomycin 227-237 LOC100508689 Homo sapiens 84-89 26143590-10 2015 Whilst further investigation is needed, it can be hypothesised that MRSA strains become hVISA during prolonged bacteraemia, which may predispose to the development of daptomycin resistance. Daptomycin 167-177 mitochondrial antiviral signaling protein Homo sapiens 88-93 23896478-2 2013 Given the variability in the penicillin-binding protein (PBP)-binding profiles of different beta-lactam antibiotics, the purpose of this study was to examine the relative enhancement of DAP activity against MRSA by different beta-lactam antibiotics to determine if a specific PBP-binding profile is associated with the ability to enhance the anti-MRSA activity of DAP. Daptomycin 186-189 AT695_RS11765 Staphylococcus aureus 57-60 24727506-13 2014 A high daptomycin MIC, as reported previously, was observed, suggesting an intrinsic resistance of Listeria spp. Daptomycin 7-17 histocompatibility minor 13 Homo sapiens 108-111 24366742-5 2014 Consistent with the observed biophysical changes, ceftaroline resulted in increased binding and killing of daptomycin-nonsusceptible VRE by human cathelicidin LL37. Daptomycin 107-117 cathelicidin antimicrobial peptide Homo sapiens 159-163 24183798-0 2014 dltA overexpression: A strain-independent keystone of daptomycin resistance in methicillin-resistant Staphylococcus aureus. Daptomycin 54-64 dihydrolipoamide S-acetyltransferase Homo sapiens 0-4 24183798-5 2014 Real-time qPCR data revealed that all DAP-resistant (DAP-R) isolates had dltA overexpression, whereas mprF upregulation was found only in DAP-R strains with the S295L and T345I amino acid substitutions. Daptomycin 38-41 dihydrolipoamide S-acetyltransferase Homo sapiens 73-77 24183798-8 2014 In conclusion, these findings highlight that dltA overexpression is the common pathway of resistance among genotypically different series of isolates and may represent the keystone of DAP resistance in MRSA, leading to electrostatic repulsion and, indirectly, to a reduction of autolysin activity. Daptomycin 184-187 dihydrolipoamide S-acetyltransferase Homo sapiens 45-49 25735844-4 2015 Lipopolysaccharide (LPS)-activated THP-1 monocytes were incubated with LIN, VAN or DAP. Daptomycin 83-86 GLI family zinc finger 2 Homo sapiens 35-40 25246437-0 2015 The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. Daptomycin 36-46 solute carrier family 9 member A6 Homo sapiens 115-119 25246437-1 2015 OBJECTIVES: We previously demonstrated that ceftaroline enhances daptomycin against MRSA in vitro. Daptomycin 65-75 solute carrier family 9 member A6 Homo sapiens 84-88 25246437-10 2015 CONCLUSIONS: These findings confirm that ceftaroline+daptomycin is a potent combination against MRSA. Daptomycin 53-63 solute carrier family 9 member A6 Homo sapiens 96-100 25239468-0 2015 Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. Daptomycin 33-43 ATP binding cassette subfamily B member 1 Homo sapiens 24-29 24329974-12 2014 The MIC to daptomycin was higher in hVISA (0.75 mug/mL vs. 0.32 mug/mL, p 0.049). Daptomycin 11-21 mitochondrial antiviral signaling protein Homo sapiens 36-41 24329974-21 2014 Caution should be employed in the empirical use of daptomycin in hVISA patients. Daptomycin 51-61 mitochondrial antiviral signaling protein Homo sapiens 65-70 24217694-7 2014 Prior exposure of vancomycin at 1 g q12h reduced the initial microbiological response of daptomycin, particularly for hVISA and VISA isolates, but did not affect the response of ceftaroline. Daptomycin 89-99 mitochondrial antiviral signaling protein Homo sapiens 118-123 24217694-7 2014 Prior exposure of vancomycin at 1 g q12h reduced the initial microbiological response of daptomycin, particularly for hVISA and VISA isolates, but did not affect the response of ceftaroline. Daptomycin 89-99 mitochondrial antiviral signaling protein Homo sapiens 119-123 24325260-14 2013 Daptomycin was found to be highly active against MRSA isolates including hVISA. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 73-78 24002096-1 2013 Single nucleotide polymorphisms (SNPs) within the mprF open reading frame (ORF) have been commonly observed in daptomycin-resistant (DAP(r)) Staphylococcus aureus strains. Daptomycin 111-121 death associated protein Homo sapiens 133-136 23992647-8 2013 Daptomycin (0.4mg/kg) in combination with Cpl-1 (0.4mg/kg) significantly increased the percentage of surviving mice at Day 7 (80%) compared with the untreated control (0%) and daptomycin or Cpl-1 monotherapy (35% and 0%, respectively). Daptomycin 0-10 plasma corticosterone level 1 Mus musculus 190-195 23992647-8 2013 Daptomycin (0.4mg/kg) in combination with Cpl-1 (0.4mg/kg) significantly increased the percentage of surviving mice at Day 7 (80%) compared with the untreated control (0%) and daptomycin or Cpl-1 monotherapy (35% and 0%, respectively). Daptomycin 176-186 plasma corticosterone level 1 Mus musculus 42-47 24068869-2 2013 Our objective was to develop an economic model from a US payer perspective that includes all direct inpatient and outpatient costs incurred by patients with MRSA cSSTI receiving linezolid, vancomycin, or daptomycin. Daptomycin 204-214 solute carrier family 9 member A6 Homo sapiens 157-167 24068869-13 2013 CONCLUSION: Outpatient costs of managing MRSA cSSTI may be reduced by 30%-50% with oral linezolid compared with vancomycin or daptomycin. Daptomycin 126-136 solute carrier family 9 member A6 Homo sapiens 41-51